A Phase 2/3 interventional study of Fecal Microbiota Transplantation in Major Depressive Disorder and Irritable Bowel Syndrome, sponsored by Valerie Taylor. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-03-19.
Sponsored by Valerie Taylor · Phase 2/3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 312 studies in Depressive Disorder, Major with a site in Canada — 66 open to participants now, 82 under way, 12 of them phase 3. Depressive Disorder, Major · Canada.
Among the 312 studies in Depressive Disorder, Major with a site in Canada, this one is the 98th largest by enrollment of the 284 interventional ones that give a count, is one of 18 that started in 2022, is one of 10 in phase 2/3, reaches primary completion later than 4 of the 81 other live ones, and was the 232nd registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →66 of the 312 studies in Depressive Disorder, Major with a site in Canada are open now. Recruiting first, the newest first:
The Royal's Institute of Mental Health Research · Sites in Canada
Ages 18–65
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–65
Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 18+
Eli Lilly and Company · Sites in Canada, United States, Australia and 12 more countries
Ages 18–75
University of Toronto · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
312 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 45 · Phase 3 76 · Phase 4 28
First in 1999; this study’s year is marked. 18 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 133 is above the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 70 across the 284 interventional studies, 120 across the 27 observational. Of the 196 that completed or were terminated, 50 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 312 have an industry lead sponsor. The 10 most frequent:
Valerie Taylor is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Valerie Taylor has 1 study filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
24 of the studies in Depressive Disorder, Major with a site in Canada that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07262008Phase 3Women's College HospitalSustained Mood Improvement With Laughing Gas Exposure | 2027-02-01 |
| NCT06891300Phase 3The Royal's Institute of Mental Health ResearchUnderstanding and Treating Suicidal Ideation With Ketamine | 2027-03 |
| NCT06963021Phase 3Neurocrine BiosciencesNBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | 2027-07 |
| NCT05423275University of British ColumbiaLight and Ion Maintenance In Treatment for Depression (LIMIT-D): Feasibility Study | 2026-12 |
| NCT06163625Unity Health TorontoThe Impact of Working Memory and Reward Markers on DLPFC Activity in Treatment-resistant Depression | 2026-12-31 |
Add all 24 to your calendar (.ics) → With an account.
Among the 312 studies in Depressive Disorder, Major with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a phase 2/3 open-label controlled trial (CT) in which adults with Major Depressive Disorder (MDD) and adults who have MDD plus comorbid Inflammatory Bowel Syndrome (IBS) will be assigned to either receive oral Fecal Microbiota Transplantation (FMT) or to continue with the treatment they are currently receiving in a Treatment As Usual (TAU) arm. An IBS alone group receiving TAU will be recruited as a clinical control group.
The primary goals of this study are to determine effectiveness, safety and tolerability of oral FMT in adults with MDD and in MDD who have comorbid IBS. Additional goals are to characterize patterns and progressions of cognitive and neural correlates associated with MDD and with MDD + IBS and to determine if they improve with FMT. It is known that both, individuals with MDD and those with MDD and IBS show cognitive alterations as well as changes in neural structures, but this study is designed to see if those are changed with treatment response to FMT. Additionally, trial feasibility will be monitored via recruitment rate, study visits adherence and participant retention to inform future trial scalability."
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Between 18-60 years of age:
Participants should be at least 18 years old and not older than 60 years at the day of screening
Exclusion Criteria:
Participant meets (DSM-5)[1] Criteria for the following conditions according to the M.I.N.I:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible and consenting patients will be assigned 1:1 to receive either FMT from a healthy donor or continuing on their usual medication for MDD, i.e., treatment as usual (TAU). This arm will continue to receive their usual anti-depressant.
Eligible and consenting patients will be assigned 1:1 to receive either FMT from a healthy donor or continuing on their usual medication for MDD, i.e., treatment as usual (TAU). This arm will be assigned to receive FMT provided by healthy donors.
Biological: Fecal Microbiota Transplantation
Biological: Fecal Microbiota Transplantation
Data from healthy comparison (HC) participants will be drawn from another completed research study. Healthy comparison participants who will best match the patient population enrolled in the current trial and who consented to data sharing will be selected.
FMT is a technique in which intestinal microbiota are transferred from a healthy screened donor to a patient, with the goal being to introduce or restore a stable microbial community in the gut.
Also known as: FMT
The Montgomery-Åsberg Depression Rating Scale (MADRS)
a 10-item questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. This will be used to evaluate the effectiveness of adjunct oral FMT as compared to TAU with currently accepted approved therapy for MDD. The MADRS overall score ranges from 0 to 60. Each item yields a score of 0 to 6 and Higher MADRS score indicates more severe depression
Time frame: Baseline to week 13
IBS Symptom Severity Scale (IBS-SSS)
The IBS-SSS is a 5-item questionnaire that is used to assess the severity and frequency of abdominal pain, severity of abdominal distention, dissatisfaction with bowel habits, and interference with quality of life over the past 10 days. Scores on the IBS-SSS can range from 0 to 500 with higher scores indicating more severe symptoms. Subjects can be categorized as having mild (75-175), moderate (175-300), or severe (\>300) IBS.
Time frame: Baseline to week 13
Toronto Side Effect Scale (TSES)
The TSES is a 32-item instrument that is designed to establish incidence, frequency, and severity of CNS, GI, and sexual side effects. For each side effect, frequency and severity are measured on a 5-point scale. intensity is measured by multiplying frequency and severity.
Time frame: Baseline to Week 13
IBS specific Quality of Life (IBS-QoL)
is a self-report 34-item instrument used to assess the impact of IBS and its treatment. used to examine GI tolerability in patients with IBS. The individual responses to the 34 items are summed and averaged for a total score and then transformed to a 0-100 scale for ease of interpretation with higher scores indicating better IBS specific quality of life.
Time frame: Baseline to Week 13
nuclear magnetic resonance (NMR) spectrometry
To assess the effect of FMT on microbiome profile (community structure and functional metagenome).
Time frame: Baseline to Week 13
structural and functional neuroimaging
fMRI to examine brain imaging changes in response to FMT
Time frame: Baseline to week 13
Number of participants recruited, and completed the study visits
trial feasibility will be monitored via recruitment rate, study visits adherence and participant retention to inform future trial scalability
Time frame: From Baseline to week 13
Plan to share: No
Ran from Apr 2022 to primary completion in Oct 2024, 30 months.
Of 16 phase 2/3 interventional studies under Depressive Disorder, Major, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 56. This study's 30 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Valerie Taylor